Fer-1 increased SLC7A11 and Nrf2 expression to resist <i>C. sinensis</i>-induced ferroptosis. by Haoyang Zhang (1706815)

Stereo Microscopy Samples (a) ABS (800 rpm,10 mm/min) (b) ABS (1200 rpm,10 mm/min) (c) ABS (1200 rpm,20 mm/min) (d) PC (800 rpm,40 mm/min) (e) PC (1200 rpm,20 mm/min).... by Shaheer Ahmed Khan (17797647)

Neural tracking of speech across linguistic timescales in relation to cognitive decline and hearing ability. by Elena Bolt (20396190)

Crack characteristics of sandstone subjected to 0 freeze-thaw cycles at loading rate of 0.05mm/min. (a) <i>t</i>_<i>p</i>-49.19s, (b) <i>t</i>_<i>p</i>-12.03s,... by Wenyu Lv (20139458)

Responses to speech onset and target nouns in relation to cognitive decline and context. by Elena Bolt (20396190)

MoCA scores distribution and audiometry results for participants. by Elena Bolt (20396190)

Speech material modulation spectrum and behavioral speech recognition task results. by Elena Bolt (20396190)

Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

“…With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”

Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

“…With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”

Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

“…With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”

Projected ASIR and ASMR of LC in China over the next 15 years based on the Bayesian APC model. by Ze-Xing Zhang (18074512)

Contribution of changes in population aging, population growth, and age-specific incidence rate to changes in incident cases of LC from 2004 to 2018 in China. by Ze-Xing Zhang (18074512)

(A) Time spent in closed arm, (B) Time spent in open arm, (C) Number of entries in closed arm, (D) Number of entries in open arm, and (E) Latency time to enter open arm for elevate... by Hammad Ismail (4227988)

Crack characteristics of sandstone subjected to 0 freeze-thaw cycles at loading rate of 0.20 mm/min. (a)<i>t</i>_<i>p</i>-29.84s, (b) <i>t</i>_<i>p</i>-5.32s, (... by Wenyu Lv (20139458)

Two-dimensional quadrant analysis of cherry shrimp (<i>N</i>. <i>davidi</i> var. red) bodycolor parameters (<i>L*</i> and <i>a*</i> values) in different feed treatment groups on da... by Wei-Wei Hou (3405947)

Effect of 0.1mM salicylic acid (SA) or hydrogen peroxide (H₂O₂) and salt treatment (0 and 75 mM NaCl) on hydrogen peroxide (H₂O₂) conten... by Amal Bouallegue (21512298)

Brown planthoppers display a distinct post mating response and male accessory gland extract induces a post-mating response. by Yi-Jie Zhang (713506)

Characterization of purified esAEVs based on protein content and the localization of Mif on the surface. by Safia A. Essien (20108379)

Rate of missing trials. by Tomoe Hayakawa (20978784)

Task design for measurement of pupillary response. by Tomoe Hayakawa (20978784)